Morgan Stanley’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67 | Buy |
298
+297
| +29,700% | +$179 | ﹤0.01% | 8025 |
|
|
2026
Q1 | $1 | Sell |
1
-12,657
| -100% | -$7.69K | ﹤0.01% | 8286 |
|
|
2025
Q4 | $8.38K | Sell |
12,658
-14,876
| -54% | -$53.7K | ﹤0.01% | 6930 |
|
|
2025
Q3 | $97.7K | Buy |
27,534
+15,387
| +127% | +$46K | ﹤0.01% | 6163 |
|
|
2025
Q2 | $24.3K | Sell |
12,147
-39,138
| -76% | -$88.9K | ﹤0.01% | 6589 |
|
|
2025
Q1 | $128K | Buy |
51,285
+34,193
| +200% | +$96.8K | ﹤0.01% | 5907 |
|
|
2024
Q4 | $50.4K | Buy |
17,092
+11,773
| +221% | +$33.1K | ﹤0.01% | 6286 |
|
|
2024
Q3 | $16K | Sell |
5,319
-547
| -9% | -$1.87K | ﹤0.01% | 6572 |
|
|
2024
Q2 | $20.4K | Sell |
5,866
-15,593
| -73% | -$67.5K | ﹤0.01% | 6450 |
|
|
2024
Q1 | $113K | Buy |
21,459
+1,885
| +10% | +$9.06K | ﹤0.01% | 5936 |
|
|
2023
Q4 | $101K | Buy |
19,574
+17,014
| +665% | +$64.4K | ﹤0.01% | 5946 |
|
|
2023
Q3 | $13.4K | Sell |
2,560
-860
| -25% | -$3.82K | ﹤0.01% | 6616 |
|
|
2023
Q2 | $6.4K | Sell |
3,420
-2,685
| -44% | -$9.41K | ﹤0.01% | 6928 |
|
|
2023
Q1 | $22.8K | Sell |
6,105
-2,208
| -27% | -$11.6K | ﹤0.01% | 6576 |
|
|
2022
Q4 | $25.7K | Buy |
8,313
+3,150
| +61% | +$11.9K | ﹤0.01% | 6569 |
|
|
2022
Q3 | $24K | Buy |
5,163
+833
| +19% | +$8.26K | ﹤0.01% | 6722 |
|
|
2022
Q2 | $114K | Sell |
4,330
-19,846
| -82% | -$701K | ﹤0.01% | 6205 |
|
|
2022
Q1 | $899K | Buy |
24,176
+12,730
| +111% | +$555K | ﹤0.01% | 5073 |
|
|
2021
Q4 | $669K | Buy |
11,446
+9,715
| +561% | +$632K | ﹤0.01% | 5374 |
|
|
2021
Q3 | $142K | Sell |
1,731
-5,253
| -75% | -$456K | ﹤0.01% | 6184 |
|
|
2021
Q2 | $660K | Sell |
6,984
-14,068
| -67% | -$1.04M | ﹤0.01% | 5346 |
|
|
2021
Q1 | $1.34M | Buy |
21,052
+20,634
| +4,936% | +$1.38M | ﹤0.01% | 4539 |
|
|
2020
Q4 | $24K | Hold |
418
| – | – | ﹤0.01% | 6381 |
|
|
2020
Q3 | $9K | Hold |
418
| – | – | ﹤0.01% | 6310 |
|
|
2020
Q2 | $7K | Hold |
418
| – | – | ﹤0.01% | 6248 |
|
|
2020
Q1 | $6K | Hold |
418
| – | – | ﹤0.01% | 6159 |
|
|
2019
Q4 | $9K | Sell |
418
-1
| -0.2% | -$25 | ﹤0.01% | 6292 |
|
|
2019
Q3 | $13K | Sell |
419
-2
| -0.5% | -$45 | ﹤0.01% | 6136 |
|
|
2019
Q2 | $9K | Buy |
421
+3
| +0.7% | +$80 | ﹤0.01% | 6172 |
|
|
2019
Q1 | $16K | Buy |
+418
| New | +$18.2K | ﹤0.01% | 6079 |
|
|
2018
Q1 | – | Sell |
-15
| Closed | – | – | 6705 |
|
|
2017
Q4 | $0 | Buy |
+15
| New | +$495 | ﹤0.01% | 6659 |
|
Other funds holding VTGN
CC
IC
AI
LM
ACM
Morgan Stanley's VTGN Position: Q2 2026 in Review
Morgan Stanley increased its VistaGen Therapeutics (VTGN) stake by 29,700% in Q2 2026, buying an estimated $179 and bringing the position to 298 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #8025.
Morgan Stanley first reported a position in VTGN in Q4 2017 and has held it in 31 quarters since. The position peaked at $1.34M in Q1 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.
- Morgan Stanley held 298 shares of VistaGen Therapeutics worth $67 as of Q2 2026.
- Morgan Stanley bought 297 VistaGen Therapeutics shares in Q2 2026, an estimated $179.
- VistaGen Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8025 holding.
- Morgan Stanley first reported a position in VistaGen Therapeutics in Q4 2017 and has held it in 31 quarters since.
- Morgan Stanley's VistaGen Therapeutics position peaked at $1.34M in Q1 2021.
- 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.